China Economic Net, Beijing, June 30th. Today, 2 new shares of United Precision (001268) and Fuyuan Pharmaceutical (601089) were listed.
United Precision (001268)
United Precision is mainly engaged in the research and development, production and sales of precision mechanical parts, including pistons, bearings, cylinders, crankshafts, etc., which are widely used in many fields such as air-conditioning compressors, refrigerator compressors and auto parts.
As of the date when the listing announcement was signed, He Junhua, He Guijing, He Yongxin and He Mingshan directly held 24 million shares, 21 million shares, 9 million shares and 6 million shares of the company respectively. The total share capital of the company is 74.12%.At the same time, He Yongxin indirectly controlled 1.90% of the company's shares through Weldon.He Guijing and He Mingshan are spouses, and He Junhua and He Yongxin are their children.He Junhua, He Guijing, He Yongxin, and He Mingshan control 76.02% of the company's shares in total, and are the company's controlling shareholder and actual controller.
The total amount of funds raised by the company in this issuance is 519 million yuan, which will be used for Guangdong Yangshan United Precision Manufacturing Co., Ltd. to add an annual output of 38 million pieces of air-conditioning compressor parts, 2 million pieces of brake discs and the expansion project of R&D center; Anhui precision parts and components Industrialization construction project; Anhui compressor shell industrialization construction project; Supplementary working capital.
Fuyuan Medicine (601089)
Fuyuan Pharmaceutical is mainly engaged in the research and development, production and sales of pharmaceutical preparations and medical devices.
Before this issuance, Xinhecheng Holding Group Co., Ltd. held 176,316,354 shares of the company, accounting for about 48.98% of the company's total share capital, and was the company's controlling shareholder.Hu Bozhen indirectly controls about 76.29% of the company's shares through Xinhecheng Holdings and Qinjin Investment, and is the actual controller of the company.
The company raised a total of 1.754 billion yuan in this issuance, which will be used for the industrialization construction project of high-precision and advanced drugs (phase I), the research and development projects of innovative drugs and generic drugs, and to supplement working capital.
(Editor in charge: Guan Jing)
